Who are Doxorubicin Hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ellence, Idamycin Pfs, Idamycin Pfs, Idamycin Pfs, Idamycin Pfs, Daunorubicin Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Doxorubicin Hydrochloride — Competitive Intelligence Brief

Doxorubicin Hydrochloride (doxorubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline Topoisomerase Inhibitor. Area: Oncology.

marketed Anthracycline Topoisomerase Inhibitor Aurora kinase A Oncology Live · refreshed every 30 min

Target snapshot

Doxorubicin Hydrochloride (doxorubicin) — Pfizer. Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxorubicin Hydrochloride TARGET	doxorubicin	Pfizer	marketed	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Ellence	EPIRUBICIN	Pfizer	marketed	Anthracycline Topoisomerase Inhibitor	Tyrosine-protein kinase Fyn	1999-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	IDARUBICIN		marketed	Anthracycline Topoisomerase Inhibitor	DNA topoisomerase 2-alpha	1990-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline Topoisomerase Inhibitor class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Meiji Seika Pharma Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxorubicin Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/doxorubicin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab